AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00842439 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBI
Description: Participants will have have one hour sessions, once a week for 12 weeks, where they will meet with an interventionist to go over cognitive-behavioral skills.
Study NCT00842439 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NUT
Description: Participants will be asked to take omega-3 supplements, calcium tablets, and multivitamins every day for 12 weeks.
Study NCT02588703 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Coping Skills Treatment
Study NCT02588703 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Existing DUI program group counseling
Study NCT04508751 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 3T Free-Breathing Fetal Magnetic Resonance Imaging
Description: Subject will have a one time MRI scan.
Study NCT04055142 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: electrocoagulation
Description: HIV homosexuals males with High-grade anal intraepithelial neoplasia will be randomized and electrocoagulation will be performed in 2-3 sessions (session every 2 weeks)
Study NCT04055142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cidofovir 1% topical ointment
Description: HIV homosexuals males with High-grade anal intraepithelial neoplasia will be randomized and they will be treated with cidofovir 1% ointment (3 times per week during 8 weeks)
Study NCT04055142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sinecatechins 10% topical ointment
Description: HIV homosexuals males with High-grade anal intraepithelial neoplasia will be randomized and they will be treated with sinecatechins 10% ointment (3 times per week during 8 weeks)
Study NCT01975337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisporivir
Description: Alisporivir supplied as 200 mg oral capsules in blister packs (7 units per blister pack)
Study NCT01975337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alisporivir
Description: Alisporivir supplied as 200 mg oral capsules in blister packs (7 units per blister pack)
Study NCT03294135 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Encepur Adults
Description: One dose of the vaccine can be administered at any one unscheduled visit depending on the detection of NT below 10. It will be administered intramuscularly into the non-dominant deltoid.
Study NCT03089879 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVGH Shigella sonnei 1790GAHB vaccine
Description: Single dose administered at Day 1, by intramuscular injection.
Study NCT03213574 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Intraoperative fluids will be administer per the discretion of anesthesia provider and not per SVV data or study protocol.
Study NCT03213574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment Group
Description: FloTrac arterial line data will be used to administer fluid bolus, based on study algorithm.
Study NCT02402049 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nux vomica
Description: 3 globules of placebo Nux vomica applied once daily at days 7,8, and 9 after the start of the period.
Study NCT02402049 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pulsatilla
Description: 3 globules of placebo Pulsatilla applied once daily at days 7,8, and 9 after the start of the period.
Study NCT03952000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A 60 minute walk at 60% maximal oxygen uptake.
Study NCT00613938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol (CG5503)
Description: 50mg capsule q4-6 hrs for 3 days
Study NCT02402049 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Folliculinum
Description: 3 globules of placebo Folliculinum applied once daily at days 7,8, and 9 after the start of the period.
Study NCT02346799 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workout Window Reminders
Description: Participants will receive emails at prespecified times reminding them to exercise, either during a specific two hour window or at any time during the day.
Study NCT02346799 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Workout Incentive Payment
Description: Participants will be paid $3 or $7 for each workout completed during the appropriate times.
Study NCT02346799 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lump Incentive Payments
Description: Participants will receive $20 payments for completing post treatment survey.
Study NCT01963598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1033 (SAR391786)
Study NCT04075968 — intervention group
Intervention type: OTHER
Intervention: Cognitive exercise
Description: Cognitive exercise will be applied
Study NCT04075968 — intervention group
Intervention type: OTHER
Intervention: Home exercise
Description: Home exercise will be applied
Study NCT01564095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Marginal liver grafts are flushed with Tacrolimus (20ng/ml) solved in 1000 ml HTK preservation solution (duration: 15 min) ex vivo at the end of backtable preparation in the experimental group.
Study NCT01564095 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HTK/Placebo
Description: Marginal liver grafts are flushed with 1000 ml HTK preservation solution(duration: 15 min) ex vivo at the end of backtable preparation in the placebo group.
Study NCT01963598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study NCT02346799 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partner Assignment
Description: Participants will be required to have same workout window as partners.
Study NCT03652493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Tumoral evaluation every 3 cycles
Study NCT01096615 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Description:~- capsule size 3~Composition of the product:~* 45 mg of microcristalline cellulose,~* 132 mg of maltodextrin,~* 3 mg of magnesium stearate.~Composition of the capsule:~* 46 mg of hypromellose,~* 1 mg of titanium dioxide.~Packaging:~Products are packaged in aluminium tubes of 30 capsules.~Storage:~The product should be stored in a fridge. Direction for use: subject should consume 1 capsule daily together with a meal, with a glass of water.~The study products will be consumed daily for 7 weeks.
Study NCT01096615 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus paracasei LP-33
Description: Description:~* minimum 2.0x109 CFU of Lactobacillus paracasei LP-33~* capsule size 3 1 capsule daily together with a meal, with a glass of water.
Study NCT01987518 — intervention group
Intervention type: OTHER
Intervention: Procedure surgery behavioral and genetic diagnosis
Description: Observational Study
Study NCT01987518 — intervention group
Intervention type: PROCEDURE
Intervention: quality of life after different type of surgery
Study NCT00718120 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluviral®
Description: One intramuscular injection into the deltoid region of the non-dominant arm
Study NCT03731767 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Distraction thrust manipulation
Description: Distraction thrust manipulation of the talocural joint in supine position
Study NCT01326455 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Terumo TR wristband
Description: A transparent unilateral compression device which is secured to the wrist via strap with velcro. The portion with the deflated 18cc balloon is placed directly over the puncture site. This balloon is inflated immediately after the catheter is removed and the balloon is inflated until bleeding visibly stops, with generally 9-18cc of air.~First deflation of 3cc of air occurred 1 hour after inflation. Deflations occurred every 15 minutes unless bleeding was noted. If bleeding was noted, balloon was reinflated (1-3cc of air) until bleeding stopped. Next deflation occurred 30 minutes later, at which point regular 15 minutes deflations occurred if no bleeding noted. Band was removed 1 hour after final deflation.
Study NCT01326455 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Terumo TR wristband
Description: A transparent unilateral compression device which is secured to the wrist via strap with velcro. The portion with the deflated 18cc balloon is placed directly over the puncture site. This balloon is inflated immediately after the catheter is removed and the balloon is inflated until bleeding visibly stops, with generally 9-18cc of air.~First balloon deflation of 3cc of air occurred 15 minutes after initial inflation. Deflations occurred every 15 minutes unless bleeding was noted. If active bleeding was noted, the balloon was re-inflated (1-3cc) until bleeding stopped. The next deflation occurred 15 minutes later. If no bleeding occurred, deflations continued every 15 minutes until the balloon was completely deflated. The band was removed 15 minutes after final deflation.
Study NCT01326455 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clo-Sur-P.A.D.
Description: A hydrophilic dressing has a high affinity for water, and absorbs and controls body fluid. The positively charged 4x4 centimetre pad reacts with the neuraminic acid residue on red blood cells causing agglutination of the cells. The Clo-Sur P.A.D. works outside of the clotting cascade.~The radial catheter was removed and occlusive pressure applied on the radial artery. Pressure was released just until bleeding noted \& the pad was applied with approximately 5 minutes of manual compression. The pad was assessed every 15 minutes for 90 minutes to ensure hemostasis. The pad was removed on post-CATH day 1.
Study NCT03072862 — intervention group
Intervention type: DEVICE
Intervention: Commercial Nucleus Cochlear Implant Systems
Description: Commercially available Nucleus Cochlear Implant Systems, including Data Logging functionality
Study NCT02762201 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PASI
Description: Implant-secured removable partial denture will be delivered in 2 large steps: implant delivery followed by denture delivery.~* Implant delivery will take 4 dental consultations : a pre-implant study at Day14 after inclusion, the surgical implant insertion at D28 after inclusion, stitches removal at D35 after inclusion, and finally functional implant delivery between 3 or 6 month after surgery (to allow implant osteointegration).~* Denture delivery will take 6 weekly dental consultations between Week 3 and Week 8 after the functional implant delivery.
Study NCT02762201 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PAC
Description: Metalic standard removable partial denture, the standard treatment, will be delivered in 4 steps at Day 7, D14, D21, D28 after inclusion, as classically.
Study NCT01078779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Chloroquine phosphate 250mg capsule, two capsules daily for 7 days then 2 capsules once a week for a total treatment duration of 12 weeks
Study NCT01078779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules, 2 capsules daily for 7 days then 2 capsules weekly for a total treatment duration of 12 weeks
Study NCT00411879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin, Epinephrine, and Steroids
Description: During resuscitation, study group patients receive vasopresssin \[20 IU IV maximum dose = 100 IU\] and methylprednisolone (40 mg IV). Epinephrine is given to both groups according to guidelines for resuscitation 2005. In the study group, postresuscitation shock is treated with stress-dose hydrocortisone.
Study NCT05827185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ergonomic modifications
Description: A blinded therapist used an observation-based ergonomics assessment check list for office workers to check the status of office environment, which usually took 40 - 45 minutes to complete. It consists of 5 domains (7 items related to office chair, 9 items related to office desk, 8 items related to keyboard and mouse, 5 items related to computer screen, 3 items related to telephone and 5 items related to the office environment -) and it has a good reliability and validity. After assessment required modifications were done in the chair, desk, keyboard, mouse, computer screen, telephone and the office environment. Ergonomic education and instructions were also given on an individual basis as per the report of the assessment.
Study NCT05827185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: First of all, hydro collator pack was applied over the neck region for 10 minutes to relax the muscles of the neck region. Then the therapist located the sites of abnormal changes in each vertebra and then cervical manipulation was given. To perform the C1-C2 cervical spine manipulation (CSM) the participant was instructed to lie in a face-up position with upper and lower extremities kept aside relaxed. The head was kept in a neutral position and the treating therapist stands at the patient's head side and holds the chin of the patient with the right side hand. The therapist left hand holds the posterior aspect of the head and does two to three free rotatory movements. Afterwards, the therapist did HVLAT technique in either the right or left direction based upon the symptoms informed by the patient.
Study NCT05827185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ergonomic modifications and Physiotherapy
Description: A blinded therapist used an observation-based ergonomics assessment check list for office workers to check the status of office environment, which usually took 40 - 45 minutes to complete. After assessment required modifications were done in the chair, desk, keyboard, mouse, computer screen, telephone and the office environment.~First of all, hydro collator pack was applied over the neck region for 10 minutes to relax the muscles of the neck region. Then the therapist located the sites of abnormal changes in each vertebra and then cervical manipulation was given.
Study NCT05827185 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Patient education
Description: Participants in the CNG group received the patient education through an experienced physiotherapist and each session lasting for 30 minutes for 4 weeks. According to each individual patients' abilities the therapist educated them to improve the health literacy regarding the condition. The therapist educated them about the benefits of self-care activities, maintaining good posture, stay active and doing active movements and stretching muscles for preventing the health related musculoskeletal injuries at the workstation. Also, life style modifications were taught to the patients to prevent further deterioration of the condition.
Study NCT01836159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iPad Intervention
Description: Patients are to self-administer 20 minutes of gaming sessions, in any configuration that is preferred. Patients will be instructed to play the iPad game with the more affected arm/hand. Start and stop times of the iPad intervention will be downloaded from the iPad, which will allow calculation of the total dose received. Patients may receive outpatient rehabilitation as required as part of usual care.~The 'Stroke Rehab' software for the iPad was specifically designed for patients with either fine motor weakness and/or neglect. It contains 6 stages:~1. Popping a stationary balloon~2. Popping a moving balloon~3. Popping a pair of stationary balloons~4. Popping a pair of moving balloons~5. Stretching a balloon to pop~6. Balloon/Text distraction test
Study NCT04520256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Intervention for Structured Physical Activity
Description: Periodic self-assessment is used to guide selection of a physical activity goal. Home-based instructional videos are provided to help meet the selected goal.
Study NCT01836159 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard/ Usual Care
Description: Patients may receive outpatient rehabilitation as required as part of usual care. Patients will be instructed not to play with an iPad during the 2 week intervention period (in case they have one).
Study NCT02959385 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Definitive Radiochemotherapy
Description: Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day
Study NCT00411879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, Epinephrine, Placebo
Description: Epinephrine is given to both groups according to guidelines for resuscitation 2005. Control group patients receive placebo instead of vasopressin and steroids.
Study NCT02959385 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Definitive Radiochemotherapy
Description: Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day
Study NCT02959385 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Radiochemotherapy
Description: Concurrent Radiochemotherapy: Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later.
Study NCT02959385 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant Radiochemotherapy
Description: Concurrent Radiochemotherapy: Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later.
Study NCT02454959 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GFF MDI (PT003) with Aerochamber
Description: Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) with Aerochamber Plus Valved Holding Chamber
Study NCT02454959 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GFF MDI (PT003) without Aerochamber
Description: Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) without Aerochamber Plus Valved Holding Chamber
Study NCT03278977 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sample for specific analyzes
Description: Standard management of ALTE~* Hospitalization in pediatric intensive care unit or pediatric emergencies~* Etiologic research~* Blood volume, 2.5mL in PaxGene® tube, for specific analyzes (M2R, AchE)
Study NCT00145145 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAGE-3.A1 peptide and CpG 7909
Study NCT03852069 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Patient receive inulin as dietary supplement (16g/d) in combination with dietary advice to restrict caloric intake and to enhance the consumption of inulin-rich vegetables
Study NCT03852069 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient receive maltodextrin as dietary supplement (16g/d) in combination with dietary advice to restrict caloric intake and to enhance the consumption of vegetables poor in inulin
Study NCT02561195 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile Vaccine
Description: 0.5 mL intramuscular injection.
Study NCT04838587 — intervention group
Intervention type: OTHER
Intervention: No intervention will be done
Description: No intervention,Only passive surveillance of Diarrhoea cases will be done
Study NCT02734472 — intervention group
Intervention type: OTHER
Intervention: Incidence and risk factors of hypertension
Description: During the follow-up period,General information(age, sex, BMI, blood pressure, the history of drink and smoke, medical history, etc).Blood biochemistry parameters（Lipid, hsCRP levels, etc）and other laboratory examination parameters(arterial stiffness,IMT, FMD) will be collected.
Study NCT02079506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan
Study NCT02079506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Study NCT00697255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corifollitropin alfa
Description: SC corifollitropin alfa on the 1st, 2nd or 3rd day after onset of a progestagen-induced withdrawal bleeding (Stage 1a: 15mcg, Stage Ib/II: 30 mcg).
Study NCT02561195 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL intramuscular injection
Study NCT00697255 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant Follicle Stimulating Hormone (recFSH)
Description: Daily injections of SC recFSH (50 IU/75 IU) administered as soon as the largest follicle reaches a size ≥12 mm 4 days after a corifollitropin alfa injection on stimulation day 5, 9 or 13.
Study NCT00697255 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human Chorion Gonadotropin (hCG)
Description: Daily injections of SC hCG (200 IU) administered as soon as the largest follicle reaches a size ≥12 mm 4 days after a corifollitropin alfa injection on stimulation day 5, 9 or 13.
Study NCT00697255 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hCG Bolus injection
Description: Bolus injection of SC hCG was administered to induce final oocyte maturation if at least one follicle is ≥18 mm and no more than two follicles ≥15 mm are observed.
Study NCT01252927 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ASIST
Description: The gatekeeper training intervention group will receive the Applied Suicide Intervention Skills Training (ASIST) workshop in addition to training as usual. ASIST is a 2-day intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide.